Montrouge, France, February 21 (10:30 p.m. CET) 2023
DBV Technologies will participate in the next AAAAI 202 3 congress
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the annual meeting of the American Academy of Allergy, Asthma and Immunology (American Academy of Allergy, Asthma, and Immunology, AAAAI), to be held February 24-27, 2023 in San Antonio, Texas. Two scientific poster presentations were accepted on the efficacy and safety data of subgroups of patients from the phase 3 EPITOPE study. DBV will also have a booth in the AAAAI exhibit hall (#1826).
The clinical data that will be presented will relate to the efficacy and safety profile of epicutaneous immunotherapy (EPIT) with Viaskin Peanut 250 µg from the phase 3 EPITOPE study in children aged 1 to 3 years allergic to peanut with or without certain comorbid atopic conditions. One poster compares efficacy and safety data in children with and without co-occurring food allergies, while the second poster focuses on children with and without atopic dermatitis.
This year the meeting will also include a non-CME Product Theater on the immunological role of the skin in food allergy. Professors Hugh Sampson, MD, of the Icahn School of Medicine at Mount Sinai, and Dr. Cecilia Berin, Ph.D., Bunning Professor for Food Allergy Research at the Feinberg School of Medicine at Northwestern University, will discuss the immune properties of the skin in relation to food allergy and the putative mechanism of epicutaneous immunotherapy, a new approach to allergen desensitization that takes advantage of the immunological functions of the skin. The “Product Theater” is scheduled for Saturday, February 25, from 10 a.m. to 10:30 a.m. CST in the AAAAI Annual Convention Exhibit Hall 2, Lobby Level.
DBV is also very pleased to sponsor the reception of the AAAAI’s FIT (Fellows-in-Training) program. This private reception will be open to current Fellows-in-Training in Allergology/Immunology on Friday, February 24 from 5:00 p.m. to 6:00 p.m. CST at the San Antonio Marriott Rivercenter, Third Floor, Grand E.
“We are proud to present Phase 3 efficacy and safety data of our epicutaneous immunotherapy in children aged 1-3 years with peanut allergy and food allergy or atopic dermatitis. comorbidity at the AAAAI Annual Meeting, as these are common comorbid allergic conditions in young children with peanut allergy,”
said Dr. Pharis Mohideen, Medical Director of DBV Technologies.
“The results demonstrate consistency in safety and efficacy across multiple patient groups, further validating the potential benefit of using the Viaskin™ platform for the treatment of peanut allergy in young children. We are excited to bring this innovative therapy to the front of the medical community and look forward to further research in young children with peanut allergy.”
Presentation and details of the abstracts:
Scientific presentations
Both e-posters will be accompanied by recorded presentations from the authors and will be available upon request at
https://annualmeeting.aaaai.org/
from Friday 25 February 2023.
Please note that only registered attendees will be able to access the Poster Room, which is available through the AAAAI Virtual Platform. After the end of the meeting, these presentations will be available on the DBV website,
www.dbv-technologies.com
for those who cannot attend.
Poster presentations
“Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study”
will be presented by David Fleischer, MD, Associate Professor of Pediatrics at Children’s Hospital Colorado.
Presentation ID: A082
Session title: Food Immunotherapy: Outcome and Mechanism
Date of presentation: Friday, February 24, 2023
Presentation time: 3:15 p.m. – 4:15 p.m. EST
Presentation location: Convention Center, Lobby Level, Hall 2
“Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study”
will be presented by Amy Scurlock, MD, Associate Professor of Pediatrics at the University of Arkansas for Medical Sciences and Arkansas Children’s Hospital.
Presentation ID: A085
Session title: Food Immunotherapy: Outcome and Mechanism
Date of presentation: Friday, February 24, 2023
Presentation time: 3:15 p.m. – 4:15 p.m. EST
Presentation location: Convention Center, Lobby Level, Hall 2
About DBV Technologies
DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).
Forward-looking statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for children with peanut allergy and the potential benefits of EPIT™, clinical development and DBV Technologies’ regulatory plans, timing and projections of VITESSE study milestones, and timing and anticipated results of interactions with regulatory agencies. All statements regarding VITESSE study milestones, recruitment, and expected outcomes contained herein are DBV’s best estimates and projections and are based on performance from prior studies. They are subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance and achievements of the VITESSE study to differ materially from the estimates and projections contained herein. document.
These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be affected by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the ‘Autorité des Marchés Financiers’ (“AMF”), DBV Technologies’ documents and reports filed with the US Securities and Exchange Commission (“SEC”) and future documents and reports filed with the AMF and the SEC. Current and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date of this document. Except as required by applicable law, DBV Technologies does not undertake to update or revise the information contained in this press release.
Contact Investor Relations
Anne Pollack
+1 (857) 529-2363
Media contacts
Angela Marcucci
+1 (646) 842-2393
[email protected]
Attachment